{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:57:29Z","timestamp":1790787449824,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171325"],"award-info":[{"award-number":["82171325"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974182"],"award-info":[{"award-number":["81974182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.nbd.2024.106632","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T20:01:15Z","timestamp":1722974475000},"page":"106632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Lymphocytes in autoimmune encephalitis: Pathogenesis and therapeutic target"],"prefix":"10.1016","volume":"200","author":[{"given":"Jiaojiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuying","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.nbd.2024.106632_bb0005","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci. Immunol."},{"issue":"7","key":"10.1016\/j.nbd.2024.106632_bb0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.nbd.2024.106632_bb0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2020-325302","article-title":"Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management","volume":"92","author":"Abboud","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"15","key":"10.1016\/j.nbd.2024.106632_bb0020","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2217\/fon.14.146","article-title":"Rituximab: modes of action, remaining dispute and future perspective","volume":"10","author":"Abulayha","year":"2014","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.nbd.2024.106632_bb0025","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1083\/jcb.128.6.1243","article-title":"The integrin VLA-4 supports tethering and rolling in flow on VCAM-1","volume":"128","author":"Alon","year":"1995","journal-title":"J. Cell Biol."},{"issue":"9","key":"10.1016\/j.nbd.2024.106632_bb0030","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.4049\/jimmunol.170.9.4497","article-title":"Determinants of human B cell migration across brain endothelial cells","volume":"170","author":"Alter","year":"2003","journal-title":"J. Immunol."},{"issue":"15","key":"10.1016\/j.nbd.2024.106632_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2024.106632_bb0040","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2020.12.014","article-title":"Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy","volume":"145","author":"Basin","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0045","article-title":"Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes","volume":"3","author":"Bastiaansen","year":"2021","journal-title":"Neurooncol. Adv."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0050","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1097\/MJT.0000000000000517","article-title":"Bortezomib for refractory immune-mediated thrombocytopenia purpura","volume":"25","author":"Beckman","year":"2018","journal-title":"Am. J. Ther."},{"issue":"7090","key":"10.1016\/j.nbd.2024.106632_bb0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"Pt 5","key":"10.1016\/j.nbd.2024.106632_bb0060","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/aws082","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume":"135","author":"Bien","year":"2012","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.nbd.2024.106632_bb0065","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.molimm.2010.03.014","article-title":"Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis","volume":"47","author":"Bitan","year":"2010","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0070","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40120-022-00327-x","article-title":"Low recruitment in a double-blind, placebo-controlled trial of ocrelizumab for autoimmune encephalitis: a case series and review of lessons learned","volume":"11","author":"Blackburn","year":"2022","journal-title":"Neurol. Ther."},{"issue":"7","key":"10.1016\/j.nbd.2024.106632_bb0075","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using cyclophosphamide in inflammatory rheumatic diseases","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur. J. Intern. Med."},{"issue":"3","key":"10.1016\/j.nbd.2024.106632_bb0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.47936\/encephalitis.2021.00052","article-title":"Proportion of peripheral regulatory T cells in patients with autoimmune encephalitis","volume":"1","author":"Byun","year":"2021","journal-title":"Encephalitis"},{"issue":"6","key":"10.1016\/j.nbd.2024.106632_bb0085","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1468-1331.2010.03180.x","article-title":"Brain immunohistopathological study in a patient with anti-NMDAR encephalitis","volume":"18","author":"Camdessanche","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2024.106632_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.antiviral.2015.09.007","article-title":"Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone","volume":"123","author":"Canivet","year":"2015","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.nbd.2024.106632_bb0095","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/JNN.0000000000000450","article-title":"Successful intrathecal rituximab administration in refractory nonteratoma anti-N-methyl-D-aspartate receptor encephalitis: a case report","volume":"51","author":"Casares","year":"2019","journal-title":"J. Neurosci. Nurs."},{"issue":"7","key":"10.1016\/j.nbd.2024.106632_bb0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.nbd.2024.106632_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5120107","article-title":"Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies","volume":"5","author":"Chen","year":"2016","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.nbd.2024.106632_bb0110","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.6.9.672","article-title":"Sydenham\u2019s chorea; a clinicopathologic study","volume":"6","author":"Colony","year":"1956","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2024.106632_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pediatrneurol.2019.09.004","article-title":"Bortezomib-responsive refractory anti-N-methyl\u2011d-aspartate receptor encephalitis","volume":"103","author":"Cordani","year":"2020","journal-title":"Pediatr. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2024.106632_bb0120","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.nbd.2024.106632_bb0125","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.nbd.2024.106632_bb0130","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0135","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.nbd.2024.106632_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2017.05.008","article-title":"Brain barriers in health and disease","volume":"107","author":"Daneman","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/neuonc\/nou126","article-title":"A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes","volume":"17","author":"de Jongste","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"12","key":"10.1016\/j.nbd.2024.106632_bb0150","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/acn3.51486","article-title":"Impact of T cells on neurodegeneration in anti-GAD65 limbic encephalitis","volume":"8","author":"Dik","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.nbd.2024.106632_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577586","article-title":"Bortezomib in anti-N-methyl\u2011d-aspartate-receptor (NMDA-R) encephalitis: a systematic review","volume":"356","author":"Dinoto","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.nbd.2024.106632_bb0160","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1767","article-title":"Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells","volume":"10","author":"Duhen","year":"2009","journal-title":"Nat. Immunol."},{"issue":"31","key":"10.1016\/j.nbd.2024.106632_bb0165","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0812530106","article-title":"IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells","volume":"106","author":"Elyaman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ni.3666","article-title":"The movers and shapers in immune privilege of the CNS","volume":"18","author":"Engelhardt","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.nbd.2024.106632_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123050","article-title":"Apheresis treatment in autoimmune neurological diseases: predictors of good clinical outcome and success of follow-up therapy with B-cell depletion","volume":"461","author":"Fousse","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.nbd.2024.106632_bb0180","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: first approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"issue":"640","key":"10.1016\/j.nbd.2024.106632_bb0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl6157","article-title":"Tissue-resident CD8(+) T cells drive compartmentalized and chronic autoimmune damage against CNS neurons","volume":"14","author":"Frieser","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.nbd.2024.106632_bb0190","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000232","article-title":"Evidence of a pathogenic role for CD8(+) T cells in anti-GABAB receptor limbic encephalitis","volume":"3","author":"Golombeck","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.nbd.2024.106632_bb0195","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0200","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2013.10.003","article-title":"Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"3","author":"Graves","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11684-015-0388-9","article-title":"Th17 cells in autoimmune diseases","volume":"9","author":"Han","year":"2015","journal-title":"Front. Med."},{"key":"10.1016\/j.nbd.2024.106632_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106682","article-title":"Low CSF CD4\/CD8+ T-cell proportions are associated with blood-CSF barrier dysfunction in limbic encephalitis","volume":"102","author":"Hansen","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.nbd.2024.106632_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107016","article-title":"CD19+ B-cells in autoantibody-negative limbic encephalitis","volume":"106","author":"Hansen","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.nbd.2024.106632_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100167","article-title":"Increased T- and B-cells associated with the phenotype of autoimmune limbic encephalitis with mainly memory dysfunction","volume":"5","author":"Hansen","year":"2022","journal-title":"J. Transl. Autoimmun."},{"issue":"9","key":"10.1016\/j.nbd.2024.106632_bb0230","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2024.106632_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101460","article-title":"Efficacy of tocilizumab for fulminant multiple sclerosis with a tumefactive cervical lesion: a 12-year-old boy","volume":"37","author":"Hoshino","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0240","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"17","key":"10.1016\/j.nbd.2024.106632_bb0245","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.nbd.2024.106632_bb0250","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.nbd.2024.106632_bb0260","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.3324\/haematol.2018.214635","article-title":"Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report","volume":"104","author":"Iversen","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.nbd.2024.106632_bb0265","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41577-021-00652-6","article-title":"B cells in central nervous system disease: diversity, locations and pathophysiology","volume":"22","author":"Jain","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"500","key":"10.1016\/j.nbd.2024.106632_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0044","article-title":"Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors","volume":"11","author":"Jones","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0275","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody","volume":"27","author":"Kang","year":"2015","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.nbd.2024.106632_bb0285","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and Treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.nbd.2024.106632_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111910","article-title":"Rapamycin alleviates mitochondrial dysfunction in anti-NMDAR encephalitis mice","volume":"132","author":"Kong","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"Pt 10","key":"10.1016\/j.nbd.2024.106632_bb0295","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/brain\/aww208","article-title":"Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis","volume":"139","author":"Kreye","year":"2016","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.nbd.2024.106632_bb0300","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamaneurol.2013.143","article-title":"Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab","volume":"70","author":"Krogias","year":"2013","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.nbd.2024.106632_bb0305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.nbd.2024.106632_bb0310","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1007\/s00415-020-09988-w","article-title":"Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review","volume":"267","author":"Lazzarin","year":"2020","journal-title":"J. Neurol."},{"issue":"0 1","key":"10.1016\/j.nbd.2024.106632_bb0315","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1007\/s10875-014-0040-5","article-title":"Unexpected targets and triggers of autoimmunity","volume":"34 Suppl 1","author":"Lee","year":"2014","journal-title":"J. Clin. Immunol."},{"issue":"18","key":"10.1016\/j.nbd.2024.106632_bb0320","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nbd.2024.106632_bb0325","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0330","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s13311-020-00921-7","article-title":"Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis","volume":"18","author":"Lee","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0335","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.nbd.2024.106632_bb0340","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/eji.201041125","article-title":"IL-9 is important for T-cell activation and differentiation in autoimmune inflammation of the central nervous system","volume":"41","author":"Li","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.nbd.2024.106632_bb0345","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2016.09.001","article-title":"New feasible treatment for refractory autoimmune encephalitis: low-dose interleukin-2","volume":"299","author":"Lim","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.nbd.2024.106632_bb0350","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.celrep.2017.10.094","article-title":"Caveolin1 is required for Th1 cell infiltration, but not tight junction remodeling, at the blood-brain barrier in autoimmune neuroinflammation","volume":"21","author":"Lutz","year":"2017","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.nbd.2024.106632_bb0355","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/acn3.444","article-title":"NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody","volume":"4","author":"Malviya","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"12","key":"10.1016\/j.nbd.2024.106632_bb0360","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0365","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/bjh.16154","article-title":"Will daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia?","volume":"187","author":"Mirgh","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.nbd.2024.106632_bb0370","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.nbd.2024.106632_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102647","article-title":"The role of TH17 cells in multiple sclerosis: therapeutic implications","volume":"19","author":"Moser","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.nbd.2024.106632_bb0380","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.nbd.2024.106632_bb0385","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0166-2236(02)02154-9","article-title":"Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases","volume":"25","author":"Neumann","year":"2002","journal-title":"Trends Neurosci."},{"issue":"14","key":"10.1016\/j.nbd.2024.106632_bb0390","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"issue":"46","key":"10.1016\/j.nbd.2024.106632_bb0395","doi-asserted-by":"crossref","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.nbd.2024.106632_bb0400","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cytogfr.2013.09.001","article-title":"Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases","volume":"24","author":"Pan","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"Pt 1","key":"10.1016\/j.nbd.2024.106632_bb0405","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/brain\/awu310","article-title":"Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice","volume":"138","author":"Planaguma","year":"2015","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.nbd.2024.106632_bb0410","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1073\/pnas.1911097117","article-title":"Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis","volume":"117","author":"Platt","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.nbd.2024.106632_bb0415","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.nbd.2024.106632_bb0420","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2010.09.002","article-title":"The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism","volume":"33","author":"Powell","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.nbd.2024.106632_bb0425","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pediatrneurol.2018.07.016","article-title":"Tocilizumab in refractory autoimmune encephalitis: a series of pediatric cases","volume":"86","author":"Randell","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.nbd.2024.106632_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.602102","article-title":"Case report: daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis","volume":"11","author":"Ratuszny","year":"2020","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2024.106632_bb0435","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ni.1716","article-title":"C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE","volume":"10","author":"Reboldi","year":"2009","journal-title":"Nat. Immunol."},{"issue":"23","key":"10.1016\/j.nbd.2024.106632_bb0440","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.nbd.2024.106632_bb0445","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/eji.200838168","article-title":"Is FOXP3 a bona fide marker for human regulatory T cells?","volume":"38","author":"Roncarolo","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.nbd.2024.106632_bb0450","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.nbd.2024.106632_bb0455","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","article-title":"B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"20","author":"Sabatino","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0460","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41583-019-0251-0","article-title":"Publisher correction: B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"21","author":"Sabatino","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0465","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2133.2000.03607.x","article-title":"Rituximab in cutaneous B-cell lymphoma: a report of two cases","volume":"143","author":"Sabroe","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.nbd.2024.106632_bb0470","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev-immunol-032414-112056","article-title":"Heterogeneity of human CD4(+) T cells against microbes","volume":"34","author":"Sallusto","year":"2016","journal-title":"Annu. Rev. Immunol."},{"issue":"20","key":"10.1016\/j.nbd.2024.106632_bb0475","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0480","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.nbd.2024.106632_bb0485","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/ene.15266","article-title":"Daratumumab for treatment-refractory antibody-mediated diseases in neurology","volume":"29","author":"Scheibe","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2024.106632_bb0490","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clineuro.2018.06.005","article-title":"Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis","volume":"172","author":"Schroeder","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"5","key":"10.1016\/j.nbd.2024.106632_bb0495","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hon.2677","article-title":"Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden","volume":"37","author":"Schwotzer","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.nbd.2024.106632_bb0500","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0505","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2010.03.004","article-title":"Amelioration of experimental autoimmune encephalitis by novel peptides: involvement of T regulatory cells","volume":"35","author":"Shapira","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.nbd.2024.106632_bb0510","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejpn.2020.10.001","article-title":"Clinical outcomes of pediatric anti-NMDA receptor encephalitis","volume":"29","author":"Shim","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"10","key":"10.1016\/j.nbd.2024.106632_bb0515","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1212\/WNL.45.10.1873","article-title":"Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice","volume":"45","author":"Sillevis Smitt","year":"1995","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0520","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neures.2007.01.006","article-title":"Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib","volume":"58","author":"Sinn","year":"2007","journal-title":"Neurosci. Res."},{"issue":"9","key":"10.1016\/j.nbd.2024.106632_bb0525","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/icb.2017.56","article-title":"IFN-gamma promotes transendothelial migration of CD4(+) T cells across the blood-brain barrier","volume":"95","author":"Sonar","year":"2017","journal-title":"Immunol. Cell Biol."},{"issue":"28","key":"10.1016\/j.nbd.2024.106632_bb0530","doi-asserted-by":"crossref","first-page":"19053","DOI":"10.1074\/jbc.M109.000521","article-title":"Caveolae-mediated internalization of occludin and claudin-5 during CCL2-induced tight junction remodeling in brain endothelial cells","volume":"284","author":"Stamatovic","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2024.106632_bb0535","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jneuroim.2017.08.011","article-title":"Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis","volume":"312","author":"Sveinsson","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0540","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.nbd.2024.106632_bb0545","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.25414","article-title":"Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders","volume":"85","author":"Thaler","year":"2019","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.nbd.2024.106632_bb0550","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.nbd.2024.106632_bb0555","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.nbd.2024.106632_bb0560","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.138.5.1627","article-title":"Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1","volume":"138","author":"van de Griend","year":"1987","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.nbd.2024.106632_bb0565","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1212\/WNL.51.4.1146","article-title":"T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis","volume":"51","author":"Voltz","year":"1998","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0570","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190460","article-title":"Pathogenic T cell cytokines in multiple sclerosis","volume":"217","author":"Wagner","year":"2020","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.nbd.2024.106632_bb0575","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/brain\/awaa250","article-title":"Autoimmune encephalitis mediated by B-cell response against N-methyl-d-aspartate receptor","volume":"143","author":"Wagnon","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0580","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.nbd.2024.106632_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577527","article-title":"Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: an observational study","volume":"354","author":"Wang","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.nbd.2024.106632_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103000","article-title":"Peripheral monocytes and soluble biomarkers in autoimmune encephalitis","volume":"135","author":"Wesselingh","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.nbd.2024.106632_bb0595","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejpn.2019.12.010","article-title":"Neurodevelopmental outcomes in paediatric immune-mediated and autoimmune epileptic encephalopathy","volume":"24","author":"Wright","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.nbd.2024.106632_bb0600","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jneuroim.2014.05.015","article-title":"The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis","volume":"273","author":"Xie","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"22","key":"10.1016\/j.nbd.2024.106632_bb0605","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2024.106632_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790962","article-title":"Immunotherapy for refractory autoimmune encephalitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Immunol."},{"issue":"6364","key":"10.1016\/j.nbd.2024.106632_bb0615","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.nbd.2024.106632_bb0620","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106632_bb0625","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12967-020-02289-w","article-title":"Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases","volume":"18","author":"Zhou","year":"2020","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.nbd.2024.106632_bb0630","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.nbd.2024.106632_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124002328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124002328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:36:41Z","timestamp":1777603001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996124002328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":127,"alternative-id":["S0969996124002328"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106632","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocytes in autoimmune encephalitis: Pathogenesis and therapeutic target","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106632"}}